Nutritional and lifestyle correlates of the cancer-protective hormone melatonin

Cancer Detection and Prevention

Volumn 31, Issue 2, 2007, Pages 140-148

  Dopfel, Regina P ^a   Schulmeister, Karl ^b   Schernhammer, Eva S ^c,d,e  

^a HARVARD UNIVERSITY   (United States)

^b ARC SEIBERSDORF RESEARCH GMBH   (Austria)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^e Applied Cancer Research Institute for Translational Research Vienna   (Austria)

Author keywords

Cancer prevention; Diet; Lifestyle factors; Melatonin; Nutrition; Onstatic mechanisms; Tryptophan

Indexed keywords

6 HYDROXYMELATONIN O SULFATE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CALMODULIN; MELATONIN; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PSYCHOTROPIC AGENT; SCAVENGER; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEX HORMONE; TRYPTOPHAN;

ALCOHOL CONSUMPTION; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; BODY MASS; CALORIC RESTRICTION; CANCER; CANCER PREVENTION; CANCER THERAPY; CIGARETTE SMOKING; CLINICAL TRIAL; CORRELATION ANALYSIS; DIETARY INTAKE; DOWN REGULATION; DRUG MECHANISM; ESTROGEN SYNTHESIS; FATTY ACID METABOLISM; FATTY ACID TRANSPORT; FRUIT; GEOGRAPHIC DISTRIBUTION; HORMONE BLOOD LEVEL; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMMUNE SYSTEM; LIFESTYLE; NIGHT WORK; NONHUMAN; NUT; NUTRITION; PARITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN DEGRADATION; RACE DIFFERENCE; SEASONAL VARIATION; SEX DIFFERENCE; SHORT SURVEY; TREATMENT RESPONSE; TUMOR CELL; VEGETABLE;

ANIMALS; DIET; FREE RADICAL SCAVENGERS; HUMANS; LIFE STYLE; MELATONIN; NEOPLASMS; NUTRITIONAL STATUS;

EID: 34247565529     PISSN: 0361090X     EISSN: 15251500     Source Type: Journal    
DOI: 10.1016/j.cdp.2007.02.001     Document Type: Short Survey

References (135)

1. Tan D.X., Manchester L.C., Reiter R.J., Qi W.B., Zhang M., Weintraub S.T., et al. Identification of highly elevated levels of melatonin in bone marrow: its origin and significance. Biochim Biophys Acta 1472 1-2 (1999) 206-214
2. Conti A., Conconi S., Hertens E., Skwarlo-Sonta K., Markowska M., and Maestroni J.M. Evidence for melatonin synthesis in mouse and human bone marrow cells. J Pineal Res 28 4 (2000) 193-202
3. Bubenik G.A. Gastrointestinal melatonin: localization, function, and clinical relevance. Dig Dis Sci 47 10 (2002) 2336-2348
4. Hardeland R., and Pandi-Perumal S.R. Melatonin, a potent agent in antioxidative defense: actions as a natural food constituent, gastrointestinal factor, drug and prodrug. Nutr Metab (Lond) 2 (2005) 22
5. Reiter R.J., Calvo J.R., Karbownik M., Qi W., and Tan D.X. Melatonin and its relation to the immune system and inflammation. Ann N Y Acad Sci 917 (2000) 376-386
6. Anisimov V.N., Popovich I.G., Zabezhinski M.A., Anisimov S.V., Vesnushkin G.M., and Vinogradova I.A. Melatonin as antioxidant, geroprotector and anticarcinogen. Biochim Biophys Acta 1757 5-6 (2006) 573-589
7. Schernhammer E.S., and Hankinson S.E. Urinary melatonin levels and breast cancer risk. J Natl Cancer Inst 97 14 (2005) 1084-1087
8. Schernhammer E.S., Kroenke C.H., Laden F., and Hankinson S.E. Night work and risk of breast cancer. Epidemiology 17 1 (2006) 108-111
9. Schernhammer E.S., Laden F., Speizer F.E., Willett W.C., Hunter D.J., Kawachi I., et al. Rotating night shifts and risk of breast cancer in women participating in the Nurses' Health Study. J Natl Cancer Inst 93 20 (2001) 1563-1568
10. Schernhammer E.S., Laden F., Speizer F.E., Willett W.C., Hunter D.J., Kawachi I., et al. Night-shift work and risk of colorectal cancer in the Nurses' Health Study. J Natl Cancer Inst 95 11 (2003) 825-888
11. Simoni R.D., Hill R.L., and Vaughan M. Nutritional biochemistry and the amino acid composition of proteins: the early years of protein chemistry. The work of Thomas B. Osborne and Lafayette B. Mendel. J Biol Chem 277 (2002) 14-15
12. Osborne T. Amino-acids in nutrition and growth. J Biol Chem 17 (1914) 325-349
13. Reiter R.J., Tan D.X., Leon J., Kilic U., and Kilic E. When melatonin gets on your nerves: its beneficial actions in experimental models of stroke. Exp Biol Med (Maywood) 230 2 (2005) 104-117
14. Lerner A.B., Case J.D., and Takahashi Y. Isolation of melatonin, a pineal factor that lightens melanocytes. J Am Chem Soc 80 (1958) 2587
15. Pandi-Perumal S.R., Srinivasan V., Maestroni G.J., Cardinali D.P., Poeggeler B., and Hardeland R. Melatonin: Nature's most versatile biological signal?. Febs J 273 13 (2006) 2813-2838
16. Hardeland R., and Fuhrberg B. Ubiquitous melatonin-presence and effects in unicells, plants, and animals. Trends Comp Biochem Physiol 2 (1996) 25-45
17. Murch S.J., Simmons C.B., and Saxena P.K. Melatonin in feverfew and other medicinal plants. Lancet 350 9091 (1997) 1598-1599
18. Manchester L.C., Tan D.X., Reiter R.J., Park W., Monis K., and Qi W. High levels of melatonin in the seeds of edible plants: possible function in germ tissue protection. Life Sci 67 25 (2000) 3023-3029
19. Cajochen C., Krauchi K., and Wirz-Justice A. Role of melatonin in the regulation of human circadian rhythms and sleep. J Neuroendocrinol 15 4 (2003) 432-437
20. Chen G., Huo Y., Tan D.X., Liang Z., Zhang W., and Zhang Y. Melatonin in Chinese medicinal herbs. Life Sci 73 1 (2003) 19-26
21. Huether G., Poeggeler B., Reimer A., and George A. Effect of tryptophan administration on circulating melatonin levels in chicks and rats: evidence for stimulation of melatonin synthesis and release in the gastrointestinal tract. Life Sci 51 12 (1992) 945-953
22. Sack R.L., Lewy A.J., Erb D.L., Vollmer W.M., and Singer C.M. Human melatonin production decreases with age. J Pineal Res 3 4 (1986) 379-388
23. Schernhammer E.S., Kroenke C.H., Dowsett M., Folkerd E., and Hankinson S.E. Urinary 6-sulfatoxy melatonin levels and their correlations with lifestyle correlates and steroid hormone levels. J Pineal Res 40 2 (2006) 116-124
24. Davis S., Kaune W.T., Mirick D.K., Chen C., and Stevens R.G. Residential magnetic fields, light-at-night, and nocturnal urinary 6-sulfatoxymelatonin concentration in women. Am J Epidemiol 154 7 (2001) 591-600
25. Youngstedt S.D., Kripke D.F., Elliott J.A., and Assmus J.D. No association of 6-sulfatoxymelatonin with in-bed 60-Hz magnetic field exposure or illumination level among older adults. Environ Res 89 3 (2002) 201-209
26. Travis R.C., Allen D.S., Fentiman I.S., and Key T.J. Melatonin and breast cancer: a prospective study. J Natl Cancer Inst 96 6 (2004) 475-482
27. Kin N.M., Nair N.P., Schwartz G., Thavundayil J.X., and Annable L. Secretion of melatonin in healthy elderly subjects: a longitudinal study. Ann N Y Acad Sci 1019 (2004) 326-329
28. Bojkowski C.J., and Arendt J. Factors influencing urinary 6-sulphatoxymelatonin, a major melatonin metabolite, in normal human subjects. Clin Endocrinol (Oxf) 33 4 (1990) 435-444
29. Iguichi H., Kato K.I., and Ibayashi H. Age-dependent reduction in serum melatonin concentrations in healthy human subjects. J Clin Endocrinol Metab 55 1 (1982) 27-29
30. Pang S.F., Tang F., and Tang P.L. Negative correlation of age and the levels of pineal melatonin, pineal N-acetylserotonin, and serum melatonin in male rats. J Exp Zool 229 1 (1984) 41-47
31. Stoschitzky K., Sakotnik A., Lercher P., Zweiker R., Maier R., Liebmann P., et al. Influence of beta-blockers on melatonin release. Eur J Clin Pharmacol 55 2 (1999) 111-115
32. Liu R.Y., Zhou J.N., van Heerikhuize J., Hofman M.A., and Swaab D.F. Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein E-epsilon4/4 genotype. J Clin Endocrinol Metab 84 1 (1999) 323-327
33. Vijayalaxmi, Thomas Jr. C.R., Reiter R.J., and Herman T.S. Melaton from basic research to cancer treatment F clinics. J Clin Oncol 20 10 (2002) 2575-2601
34. Sanchez-Barcelo E.J., Cos S., Fernandez R., and Mediavilla M.D. Melatonin and mammary cancer: a short review. Endocr Relat Cancer 10 2 (2003) 153-159
35. Cavallo A., Daniels S.R., Dolan L.M., Bean J.A., and Khoury J.C. Blood pressure-lowering effect of melatonin in type 1 diabetes. J Pineal Res 36 4 (2004) 262-266
36. Mayo J.C., Sainz R.M., Tan D.X., Antolin I., Rodriguez C., and Reiter R.J. Melatonin and Parkinson's disease. Endocrine 27 2 (2005) 169-178
37. Dowling G.A., Mastick J., Colling E., Carter J.H., Singer C.M., and Aminoff M.J. Melatonin for sleep disturbances in Parkinson's disease. Sleep Med 6 5 (2005) 459-466
38. Wu Y.H., and Swaab D.F. The human pineal gland and melatonin in aging and Alzheimer's disease. J Pineal Res 38 3 (2005) 145-152
39. Pappolla M.A., Chyan Y.J., Poeggeler B., Frangione B., Wilson G., Ghiso J., et al. An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: implications for Alzheimer's disease. J Neural Transm 107 2 (2000) 203-231
40. Cardinali D.P., Brusco L.I., Liberczuk C., and Furio A.M. The use of melatonin in Alzheimer's disease. Neuro Endocrinol Lett 23 Suppl 1 (2002) 20-23
41. Cheng Y., Feng Z., Zhang Q.Z., and Zhang J.T. Beneficial effects of melatonin in experimental models of Alzheimer disease. Acta Pharmacol Sin 27 2 (2006) 129-139
42. Reiter R.J., Acuna-Castroviejo D., Tan D.X., and Burkhardt S. Free radical-mediated molecular damage mechanisms for the protective actions of melatonin in the central nervous system. Ann N Y Acad Sci 939 (2001) 200-215
43. Chyan Y.J., Poeggeler B., Omar R.A., Chain D.G., Frangione B., Ghiso J., et al. Potent neuroprotective properties against the Alzheimer beta-amyloid by an endogenous melatonin-related indole structure, indole-3-propionic acid. J Biol Chem 274 31 (1999) 21937-21942
44. Sandyk R., Anastasiadis P.G., Anninos P.A., and Tsagas N. Is postmenopausal osteoporosis related to pineal gland functions?. Int J Neurosci 62 3-4 (1992) 215-225
45. Schernhammer E.S., Rosner B., Willett W.C., Laden F., Colditz G.A., and Hankinson S.E. Epidemiology of urinary melatonin in women and its relation to other hormones and night work. Cancer Epidemiol Biomarkers Prev 13 6 (2004) 936-943
46. Levallois P., Dumont M., Touitou Y., Gingras S., Masse B., Gauvin D., et al. Effects of electric and magnetic fields from high-power lines on female urinary excretion of 6-sulfatoxymelatonin. Am J Epidemiol 154 7 (2001) 601-609
47. Waldhauser F., Weiszenbacher G., Frisch H., Zeitlhuber U., Waldhauser M., and Wurtman R.J. Fall in nocturnal serum melatonin during prepuberty and pubescence. Lancet 18 1 (1984) 362-365
48. Reiter R.J. The pineal and its hormones in the control of reproduction in mammals. Endocr Rev 1 2 (1980) 109-131
49. Burch J.B., Yost M.G., Johnson W., and Allen E. Melatonin, sleep, and shift work adaptation. J Occup Environ Med 47 9 (2005) 893-901
50. Cocco P., Cocco M.E., Paghi L., Avataneo G., Salis A., Meloni M., et al. Urinary 6-sulfatoxymelatonin excretion in humans during domestic exposure to 50 hertz electromagnetic fields. Neuro Endocrinol Lett 26 2 (2005) 136-142
51. Schernhammer E.S., Kroenke C.H., Dowsett M., Folkerd E., and Hankinson S.E. Urinary 6-sulfatoxymelatonin levels and their correlations with lifestyle factors and steroid hormone levels. J Pineal Res 40 2 (2006) 116-124
52. Fideleff H.L., Boquete H., Fideleff G., Albornoz L., Lloret S.P., Suarez M., et al. Gender-related differences in urinary 6-sulfatoxymelatonin levels in obese pubertal individuals. J Pineal Res 40 3 (2006) 214-218
53. Dubbels R., Reiter R.J., Klenke E., Goebel A., Schnakenberg E., Ehlers C., et al. Melatonin in edible plants identified by radioimmunoassay and by high performance liquid chromatography-mass spectrometry. J Pineal Res 18 1 (1995) 28-31
54. Hattori A., Migitaka H., Iigo M., Itoh M., Yamamoto K., Ohtani-Kaneko R., et al. Identification of melatonin in plants and its effects on plasma melatonin levels and binding to melatonin receptors in vertebrates. Biochem Mol Biol Int 35 3 (1995) 627-634
55. Reiter R.J., and Kim S.J. Phytochemicals: melatonin (1999), Wiley, New York
56. Balzer I., and Hardeland R. Melatonin in green plants. In: Hardeland R. (Ed). Cellular rhythms and indolamines (1995), University of Göttingen, Göttingen 152-161
57. Burkhardt S., Tan D.X., Manchester L.C., Hardeland R., and Reiter R.J. Detection and quantification of the antioxidant melatonin in Montmorency and Balaton tart cherries (Prunus cerasus). J Agric Food Chem 49 10 (2001) 4898-4902
58. Reiter R.J., Tan D.X., Burkhardt S., and Manchester L.C. Melatonin in plants. Nutr Rev 59 9 (2001) 286-290
59. Reiter R.J., and Tan D.X. Melatonin: an antioxidant in edible plants. Ann N Y Acad Sci 957 (2002) 341-344
60. Bediz C.S., Baltaci A.K., and Mogulkoc R. Both zinc deficiency and supplementation affect plasma melatonin levels in rats. Acta Physiol Hung 90 4 (2003) 335-339
61. Fournier I., Ploye F., Cottet-Emard J.M., Brun J., and Claustrat B. Folate deficiency alters melatonin secretion in rats. J Nutr 132 9 (2002) 2781-2784
62. 2+ and high-calorie food on the synthesis and intensity of the secretion of melatonin. Georgian Med News 132 (2006) 121-123
63. Reiter R.J., Manchester L.C., and Tan D.X. Melatonin in walnuts: influence on levels of melatonin and total antioxidant capacity of blood. Nutrition 21 9 (2005) 920-924
64. Nagata C., Nagao Y., Shibuya C., Kashiki Y., and Shimizu H. Association of vegetable intake with urinary 6-sulfatoxymelatonin level. Cancer Epidemiol Biomarkers Prev 14 5 (2005) 1333-1335
65. Mattison J.A., Lane M.A., Roth G.S., and Ingram D.K. Calorie restriction in rhesus monkeys. Exp Gerontol 38 1-2 (2003) 35-46
66. Roth G.S., Lesnikov V., Lesnikov M., Ingram D.K., and Lane M.A. Dietary caloric restriction prevents the age-related decline in plasma melatonin levels of rhesus monkeys. J Clin Endocrinol Metab 86 7 (2001) 3292-3295
67. Selmaoui B., Oguine A., and Thibault L. Food access schedule and diet composition alter rhythmicity of serum melatonin and pineal NAT activity. Physiol Behav 74 4-5 (2001) 449-455
68. Sotak M., Mrnka L., and Pacha J. Heterogeneous expression of melatonin receptor MT1 mRNA in the rat intestine under control and fasting conditions. J Pineal Res 41 2 (2006) 183-188
69. Michalsen A., Schlegel F., Rodenbeck A., Ludtke R., Huether G., Teschler H., et al. Effects of short-term modified fasting on sleep patterns and daytime vigilance in non-obese subjects: results of a pilot study. Ann Nutr Metab 47 5 (2003) 194-200
70. Berga S.L., Loucks T.L., and Cameron J.L. Endocrine and chronobiological effects of fasting in women. Fertil Steril 75 5 (2001) 926-932
71. Wetterberg L., Halberg F., Tarquini B., Cagnoni M., Haus E., Griffith K., et al. Circadian variation in urinary melatonin in clinically healthy women in Japan and the United States of America. Experientia 35 3 (1979) 416-419
72. Sandyk R., Anastasiadis P.G., Anninos P.A., and Tsagas N. Is the pineal gland involved in the pathogenesis of endometrial carcinoma. Int J Neurosci 62 1-2 (1992)
73. Kunz D., Schmitz S., Mahlberg R., Mohr A., Stoter C., Wolf K.J., et al. A new concept for melatonin deficit: on pineal calcification and melatonin excretion. Neuropsychopharmacology 21 6 (1999) 765-772
74. Molina-Carballo A., Munoz-Hoyos A., Martin-Garcia J.A., Uberos-Fernandez J., Rodriguez-Cabezas T., and Acuna-Castroviejo D. 5-Methoxytryptophol and melatonin in children: differences due to age and sex. J Pineal Res 21 2 (1996) 73-79
75. Leppaluoto J.S.K., Meyer-Rochow V.B., and Hassi J. Spring snow lowers human melatonin. Int J Circumpolar Health 63 Suppl 2 (2004) 161-163
76. Kivela A., Kauppila A., Ylostalo P., Vakkuri O., and Leppaluoto J. Seasonal, menstrual and circadian secretions of melatonin, gonadotropins and prolactin in women. Acta Physiol Scand 132 3 (1988) 321-327
77. Bratlid T., and Wahlund B. Alterations in serum melatonin and sleep in individuals in a sub-arctic region from winter to spring. Int J Circumpolar Health 62 3 (2003) 242-254
78. Sivan Y., Laudon M., Tauman R., and Zisapel N. Melatonin production in healthy infants: evidence for seasonal variations. Pediatr Res 49 1 (2001) 63-68
79. Leppaluoto J. Association of melatonin secretion with seasonal luminosity in human subjects. Int J Circumpolar Health 62 3 (2003) 223-227
80. Cutolo M., Maestroni G.J., Otsa K., Aakre O., Villaggio B., Capellino S., et al. Circadian melatonin and cortisol levels in rheumatoid arthritis patients in winter time: a north and south Europe comparison. Ann Rheum Dis 64 2 (2005) 212-216
81. Wetterberg L., Bratlid T., von Knorring L., Eberhard G., and Yuwiler A. A multinational study of the relationships between nighttime urinary melatonin production, age, gender, body size, and latitude. Eur Arch Psychiatry Clin Neurosci 249 5 (1999) 256-262
82. Ozguner F., Koyu A., and Cesur G. Active smoking causes oxidative stress and decreases blood melatonin levels. Toxicol Ind Health 21 1-2 (2005) 21-26
83. Ursing C., von Bahr C., Brismar K., and Rojdmark S. Influence of cigarette smoking on melatonin levels in man. Eur J Clin Pharmacol 61 3 (2005) 197-201
84. Ronkainen H., Vakkuri O., and Kauppila A. Effects of physical exercise on the serum concentration of melatonin in female runners. Acta Obstet Gynecol Scand 65 8 (1986) 827-829
85. Lucia A., Diaz B., Hoyos J., Fernandez C., Villa G., Bandres F., et al. Hormone levels of world class cyclists during the Tour of Spain stage race. Br J Sports Med 35 6 (2001) 424-430
86. Barger L.K., Wright K.P.J., Hughes R.J., and Czeisler C.A. Daily exercise facilitates phase delays of circadian melatonin rhythm in very dim light. Am J Physiol Regul Integr Comp Physiol 286 6 (2004) R1077-R1084
87. Danforth D.N.J., Tamarkin L., Mulvihill J.J., Bagley C.S., and Lippman M.E. Plasma melatonin and the hormone-dependency of human breast cancer. J Clin Oncol 3 7 (1985) 941-948
88. Cook M.R., Graham C., Kavet R., Stevens R.G., Davis S., and Kheifets L. Morning urinary assessment of nocturnal melatonin secretion in older women. J Pineal Res 28 1 (2000) 41-47
89. Stoschitzky K., Sakotnik A., Lercher P., Zweiker R., Maier R., Liebmann P., et al. Influence of beta-blockers on melatonin release. Eur J Clin Pharmacol 55 (1999) 111-115
90. Murphy D.L., Garrick N.A., Tamarkin L., Taylor P.L., and Markey S.P. Effects of antidepressants and other psychotropic drugs on melatonin release and pineal gland function. J Neural Transm 21 (1986) 291-309
91. Murphy P.J., Myers B.L., and Badia P. Nonsteroidal anti-inflammatory drugs alter body temperature and suppress melatonin in humans. Physiol Behav 59 (1996) 133-139
92. Brismar K., Hylander B., Eliasson K., Rossner S., and Wetterberg L. Melatonin secretion related to side-effects of beta-blockers from the central nervous system. Acta Med Scand 223 6 (1988) 525-530
93. Maestroni G.J. The immunotherapeutic potential of melatonin. Expert Opin Investig Drugs 10 3 (2001) 467-476
94. Benot S., Goberna R., Reiter R.J., Garcia-Maurino S., Osuna C., and Guerrero J.M. Physiological levels of melatonin contribute to the antioxidant capacity of human serum. J Pineal Res 27 1 (1999) 59-64
95. Tan D., Reiter R.J., Chen L.D., Poeggeler B., Manchester L.C., and Barlow-Walden L.R. Both physiological and pharmacological levels of melatonin reduce DNA adduct formation induced by the carcinogen safrole. Carcinogenesis 15 2 (1994) 215-218
96. Tan D.X., Manchester L.C., Reiter R.J., Plummer B.F., Hardies L.J., Weintraub S.T., et al. A novel melatonin metabolite, cyclic 3-hydroxymelatonin: a biomarker of in vivo hydroxyl radical generation. Biochem Biophys Res Commun 253 3 (1998) 614-620
97. Hill S.M., and Blask D.E. Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture. Cancer Res 48 21 (1988) 6121-6126
98. Cos S., Fernandez F., and Sanchez-Barcelo E.J. Melatonin inhibits DNA synthesis in MCF-7 human breast cancer cells in vitro. Life Sci 58 26 (1996) 2447-2453
99. Cos S., Fernandez R., Guezmes A., and Sanchez-Barcelo E.J. Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells. Cancer Res 58 (1998) 4383-4390
100. Mediavilla M.D., Cos S., and Sanchez-Barcelo E.J. Melatonin increases p53 and p21WAF1 expression in MCF-7 human breast cancer cells in vitro. Life Sci 65 4 (1999) 415-420
101. Cos S., Gonzalez A., Martinez-Campa C., Mediavilla M.D., Alonso-Gonzalez C., and Sanchez-Barcelo E.J. Estrogen-signaling pathway: a link between breast cancer and melatonin oncostatic actions. Cancer Detect Prev 30 2 (2006) 118-128
102. Ying S.W., Niles L.P., and Crocker C. Human malignant melanoma cells express high-affinity receptors for melatonin: antiproliferative effects of melatonin and 6-chloromelatonin. Eur J Pharmacol 246 2 (1993) 89-96
103. Sze S.F., Ng T.B., and Liu W.K. Antiproliferative effect of pineal indoles on cultured tumor cell lines. J Pineal Res 14 1 (1993) 27-33
104. Shiu S.Y., Li L., Xu J.N., Pang C.S., Wong J.T., and Pang S.F. Melatonin-induced inhibition of proliferation and G1/S cell cycle transition delay of human choriocarcinoma JAr cells: possible involvement of MT2 (MEL1B) receptor. Pineal Res 27 3 (1999) 183-192
105. Petranka J., Baldwin W.S., Bierman J., Jayadev S., Barrett J.C., and Murphy E. The oncostatic action of melatonin in an ovarian carcinoma cell line. Pineal Res 26 (1999) 129-136
106. Kanishi Y., Kobayashi Y., Noda S., Ishizuka B., and Saito K. Differential growth inhibitory effect of melatonin on two endometrial cancer cell lines. J Pineal Res 28 4 (2000) 227-233
107. Tamarkin L., Cohen M., Roselle D., Reichert C., Lippman M., and Chabner B. Melatonin inhibition and pinealectomy enhancement of 7,12-dimethylbenz(a)anthracene-induced mammary tumors in the rat. Cancer Res 41 11 Pt 1 (1981) 4432-4436
108. Musatov S.A., Anisimov V.N., Andre V., Vigreux C., Godard T., and Sichel F. Effects of melatonin on N-nitroso-N-methylurea-induced carcinogenesis in rats and mutagenesis in vitro (Ames test and COMET assay). Cancer Lett 138 (1999) 37-44
109. Cini G., Coronnello M., Mini E., and Neri B. Melatonin's growth-inhibitory effect on hepatoma AH 130 in the rat. Cancer Lett 125 1-2 (1998) 51-59
110. Mocchegiani E., Perissin L., Santarelli L., Tibaldi A., Zorzet S., Rapozzi V., et al. Melatonin administration in tumor-bearing mice (intact and pinealectomized) in relation to stress, zinc, thymulin and IL-2. Int J Immunopharmacol 21 1 (1999) 27-46
111. Anisimov V.N., Popovich I.G., and Zabezhinski M.A. Melatonin and colon carcinogenesis. I. Inhibitory effect of melatonin on development of intestinal tumors induced by 1,2-dimethylhydrazine in rats. Carcinogenesis 18 (1997) 1549-1553
112. Anisimov V.N., Kvetnoy I.M., Chumakova N.K., Kvetnaya T.V., Molotkov A.O., Pogudina N.A., et al. Melatonin and colon carcinogenesis. Exp Toxicol Pathol 51 (1999) 47-52
113. Blask D.E., Brainard G.C., Dauchy R.T., Hanifin J.P., Davidson L.K., Krause J.A., et al. Melatonin-depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenografts in nude rats. Cancer Res 65 23 (2005) 11174-11184
114. Poeggeler B., Reiter R.J., Hardeland R., Sewerynek E., Melchiorri D., and Barlow-Walden L. Melatonin, a mediator of electron transfer and repair reactions, acts synergistically with the chainbreaking antioxidants ascorbate, trolox and glutathione. Neuro Endocrinol Lett 17 (1995) 87-92
115. Reiter R.J., Melchiorri D., Sewerynek E., Poeggeler B., Barlow-Walden L., Chuang J., et al. A review of the evidence supporting melatonin's role as an antioxidant. J Pineal Res 18 1 (1995) 1-11
116. Poeggeler B., Reiter R.J., Tan D.X., Chen L.D., and Manchester L.C. Melatonin, hydroxyl radical-mediated oxidative damage, and aging: a hypothesis. J Pineal Res 14 4 (1993) 151-168
117. Hardeland R., Reiter R.J., Poeggeler B., and Tan D.X. The significance of the metabolism of the neurohormone melatonin: antioxidative protection and formation of bioactive substances. Neurosci Biobehav Rev 17 3 (1993) 347-357
118. Cardinali D.P., Ladizesky M.G., Boggio V., Cutrera R.A., and Mautalen C. Melatonin effects on bone: experimental facts and clinical perspectives. J Pineal Res 34 2 (2003) 81-87
119. Sainz R.M., Mayo J.C., Rodriguez C., Tan D.X., Lopez-Burillo S., and Reiter R.J. Melatonin and cell death: differential actions on apoptosis in normal and cancer cells. Cell Mol Life Sci 60 7 (2003) 1407-1426
120. Blask D.E., Sauer L.A., and Dauchy R.T. Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr Trop Med Chem 2 2 (2002) 113-132
121. Lissoni P., Rovelli F., Malugani F., Bucovec R., Conti A., and Maestroni G.J. Anti-angiogenic activity of melatonin in advanced cancer patients. Neuro Endocrinol Lett 22 1 (2001) 45-47
122. Vijayalaxmi, Thomas C.R.J., Reiter R.J., and Herman T.S. Melatonin: from basic research to cancer treatment clinics. J Clin Oncol 20 10 (2002) 2575-2601
123. Stevens R.G. Electric power use and breast cancer: a hypothesis. Am J Epidemiol 125 4 (1987) 556-561
124. Ram P.T., Dai J., Yuan L., Dong C., Kiefer T.L., Lai L., et al. Involvement of the mt1 melatonin receptor in human breast cancer. Cancer Lett 179 2 (2002) 141-150
125. Yuan L., Collins A.R., Dai J., Dubocovich M.L., and Hill S.M. MT1 melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells. Mol Cell Endocrinol 192 1-2 (2002) 147-156
126. Molis T.M., Spriggs L.L., and Hill S.M. Modulation of estrogen receptor mRNA expression by melatonin in MCF-7 human breast cancer cells. Mol Endocrinol 8 12 (1994) 1681-1690
127. Rato A.G., Pedrero J.G., Martinez M.A., del Rio B., Lazo P.S., and Ramos S. Melatonin blocks the activation of estrogen receptor for DNA binding. FASEB J 13 8 (1999) 857-868
128. Lawson N.O., Wee B.E., Blask D.E., Castles C.G., Spriggs L.L., and Hill S.M. Melatonin decreases estrogen receptor expression in the medial preoptic area of inbred (LSH/SsLak) golden hamsters. Biol Reprod 47 6 (1992) 1082-1090
129. Cohen M., Lippman M., and Chabner B. Role of pineal gland in aetiology and treatment of breast cancer. Lancet 2 8094 (1978) 814-816
130. Stevens R.G., and Davis S. The melatonin hypothesis: electric power and breast cancer. Environ Health Perspect 104 (1996) 135-140
131. Stevens R.G., Davis S., Thomas D.B., Anderson L.E., and Wilson B.W. Electric power, pineal function, and the risk of breast cancer. FASEB J 6 3 (1992) 853-860
132. Cos S., Martinez-Campa C., Mediavilla M.D., and Sanchez-Barcelo E.J. Melatonin modulates aromatase activity in MCF-7 human breast cancer cells. J Pineal Res 38 2 (2005) 136-142
133. Cos S, Gonzalez A, Guezmes A, Mediavilla MD, Martinez-Campa C, Alonso-Gonzalez C, et al. Melatonin inhibits the growth of DMBA-induced mammary tumors by decreasing the local biosynthesis of estrogens through the modulation of aromatase activity. Int J Cancer 2005.
134. Kiefer T., Ram P.T., Yuan L., and Hill S.M. Melatonin inhibits estrogen receptor transactivation and cAMP levels in breast cancer cells. Breast Cancer Res 71 1 (2002) 37-45
135. Smith K.A., Schoen M.W., and Czeisler C.A. Adaptation of human pineal melatonin suppression by recent photic history. J Clin Endocrinol Metab 89 7 (2004) 3610-3614